OLIPASS Corporation

₩1,651As of Sun 8 Nov 2026, 12:00 UTC
KOSDAQ:244460Healthcare
Country South Korea
PE (Fwd) •••
TSR 7Y CAGR (45.54%)
Div yield —
ROE (216.38%)
Biological Products, Except Diagnostic Substances
Beta (5Y) (0.37)
PE TTM —
TSR TTM —
Mkt cap ₩8.401B
ROIC (577.99%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩2,133
29.17%
(58.03%)
Buy 3|1|6|6|2
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
23.24
25.81
25.76
24.63
9.48%
25.37%
19.28%
2.65%
Revenue₩M
506.2
524.8
523.8
536.4
0.50%
3.74%
(0.80%)
2.87%
Peers (US$6.194M)
Cap (US$)
PE
14.83M
—
8.788M
—
Capital
TTM
5Y
10Y
Leveragex
1.234
(0.530)
(0.378)
EBIT/Intx
1.955
0.091
0.090
Own earn%
43.43
27.98
32.87
Sh yield%
48.21
27.24
28.76
Owners
Insiders/Inst%
8.17
73.23
Short interest%
3.12
SBC / revenue%
2.91
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
16–19
$1 testx
0.0
Incr. ROIC%
5